REGENXBIO adds Greg Ciongoli to board, two directors depart

REGENXBIO Inc. announced on August 25, 2026 that Greg Ciongoli was appointed to its Board of Directors, effective August 25, 2026.¹ Under the company's SEC filing, the Board elected Gregory Ciongoli as a Class II director effective immediately, with an initial term set to expire at the 2029 annual meeting of stockholders.¹ The company said the Board determined Ciongoli to be independent under SEC and Nasdaq rules and appointed him to the Audit Committee and the Nominating and Corporate Governance Committee.¹

His compensation package includes an initial equity award with an aggregate grant date fair value of $550,000, split 75% as a non-statutory stock option and 25% as restricted stock units, with the option carrying an exercise price of $8.91 per share.¹ He will also receive a $45,000 annual board retainer plus $10,000 and $5,000 annual retainers for his Audit Committee and Nominating and Corporate Governance Committee service, respectively.¹

Concurrently, Jerry Karabelas, Ph.D., an independent director since 2015, and Jean Bennett, M.D., Ph.D., an independent director since 2021, are retiring from the Board.¹ Per the filing, the Board accepted the resignations of both directors effective August 25, 2026.¹ The company added that both departing directors are set to remain available to the Board in an advisory capacity through February 2027, a period that could be extended.¹ As a result of these changes, the Board reduced its overall size to nine directors, effective immediately.¹

Ciongoli is Founder and Managing Partner of Adiumentum Capital Management¹ and previously spent over 16 years at The Baupost Group, where he served as Partner, Public Group Investing.¹ He currently serves as Board Chairman of Atara Biotherapeutics and is also a Board member at Zymeworks Inc.¹